期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 3, 页码 844-847出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI46399
关键词
-
资金
- NHLBI NIH HHS [R01 HL071207, HL71207] Funding Source: Medline
- Telethon [GGP10020] Funding Source: Medline
In this issue of the JCI, Wu et al. and Mann et al. describe two new mouse models of inherited disorders of the RAS/MAPK signal transduction pathway that display hypertrophic cardiomyopathy (HCM); the model from the former paper was from a gain-of-function Raf1 mutation, and the model from the latter paper was from a protein tyrosine phosphatase, non-receptor type 11 (Ptpn11) mutated allele encoding Shp2 with impaired catalytic function. The two groups show that HCM arises from increased signaling through Erk1/2 and the mTor complex 1, respectively, and that those cardiac issues can be prevented or reversed with small-molecule therapies inhibiting the appropriate pathway. Aside from being the first studies of treatment for Noonan syndrome and related disorders in a mammalian system, these papers provide important insights into the role of RAS signaling in cardiac hypertrophy and suggest the complexity in developing meaningful therapy for individuals with these RASopathies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据